Elite Pharmaceuticals Launches Generic Vyvanse®: A Major Step Forward in ADHD Treatment

Northvale, NJ – Elite Pharmaceuticals, Inc. (OTCQB: ELTP), a specialty pharmaceutical company known for its niche generic products, announced the commercial launch of its generic version of Vyvanse® (Lisdexamfetamine Disylate). 

This highly anticipated product is now available in multiple strengths—10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg capsules—offering a comprehensive treatment solution for individuals managing attention deficit hyperactivity disorder (ADHD). The product will be marketed and distributed under the Elite Laboratories, Inc. label.

With ADHD impacting millions, Elite’s generic Vyvanse® aims to provide an accessible and effective alternative to the branded medication. According to IQVIA, the original product recorded annual sales of approximately $4.3 billion for the twelve months ending October 2024, highlighting the significant demand and impact of this treatment option.

A Leader in Niche Generics
Elite Pharmaceuticals has carved a reputation for developing and manufacturing high-quality, niche generic products. The company operates a cGMP and DEA-registered facility in Northvale, NJ, where its team focuses on delivering both immediate-release and controlled-release solid oral dose medications. These products are marketed under the Elite Laboratories label or through partnerships with third-party distributors.